Keeps BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Keeps a Legitimate Telehealth Service?

Keeps operates as a legitimate telehealth and pharmacy platform focused on male androgenetic alopecia. It connects patients with licensed physicians and nurse practitioners across all 50 states, then fulfills prescriptions through licensed, LegitScript-certified pharmacy partners. The drugs it prescribes, finasteride 1 mg and minoxidil, carry full FDA approval for male pattern hair loss.

Telehealth legitimacy has two distinct dimensions: regulatory compliance and consumer experience. Keeps clears the first bar clearly. Consumer experience is more variable, as the complaint data below shows.

Regulatory and Licensing Baseline

Licensed prescribers in each state must hold an active state medical license to write prescriptions for patients in that jurisdiction. Keeps' prescribing model relies on asynchronous telehealth consultations, photo-based assessments submitted through the app. This model is legal under most state telehealth statutes, though a handful of states require a synchronous visit before issuing a controlled substance or Schedule-adjacent medication.

Finasteride is not a controlled substance. The FDA approved finasteride 1 mg (brand name Propecia) for male pattern hair loss in 1997, and generic versions have been available since 2006 [1]. Minoxidil 2% and 5% topical solutions are available OTC and carry FDA approval dating to 1988 [2].

LegitScript and Pharmacy Compliance

LegitScript, the verification body used by Google, Meta, and major payment processors, certifies online pharmacies that meet state licensing, prescription-requirement, and patient-safety standards. Keeps' dispensing pharmacy partners carry this certification. Without it, Keeps could not legally advertise on Google or process payments through major card networks, a meaningful compliance bar.

No FDA warning letters addressed to Keeps or its pharmacy partners appear in the FDA enforcement database as of mid-2025 [3].

What Does the BBB Record Actually Show?

The Better Business Bureau profile for Keeps Health, Inc. Is publicly searchable. As of mid-2025, Keeps is not BBB-accredited. The profile carries a mix of resolved and unresolved complaints. The pattern across complaint narratives is consistent: the dominant categories are billing transparency, auto-renewal surprises, difficulty canceling subscriptions, and delayed or missing shipments. Clinical harm complaints represent a small minority of total filings.

Complaint Volume in Context

BBB complaint counts are an imperfect metric. Volume alone does not indicate danger; it often tracks customer base size and subscription-model friction. Subscription health brands, across every category, generate disproportionately high BBB complaint rates relative to one-time-purchase retailers, because the cancellation and billing lifecycle creates multiple friction points. That pattern holds for Keeps.

The complaint profile does not include FDA MedWatch adverse event reports tied to counterfeit or adulterated product, which would be the signal that matters most for patient safety.

Auto-Renewal and Cancellation Complaints

The most frequently cited grievance in Keeps' BBB file is unexpected auto-renewal charges after users believed they had canceled. Several consumers report that cancellation requires a support chat or email exchange rather than a one-click portal option, a design choice that generates real frustration and maps directly to FTC guidance on "negative option" subscription practices [4].

The FTC's Negative Option Rule, updated in 2023, requires that cancellation be as easy as sign-up. Companies that bury cancellation behind support queues face regulatory exposure. Keeps has reportedly improved cancellation flow since 2023, though consumer reports remain mixed.

Shipping and Prescription-Lag Complaints

A secondary cluster of complaints involves shipping delays, particularly for first-time prescriptions, where the asynchronous consult review window (typically 24 to 48 hours) adds to fulfillment time. Some consumers report confusion between the medical consultation timeline and the shipping timeline, expecting same-day dispatch after completing their intake form.

This is largely a communication problem, not a clinical one. Asynchronous telehealth consults legally cannot guarantee immediate prescription issuance because a licensed clinician must independently review each case.

Finasteride Safety: What the Clinical Evidence Says

Understanding complaint patterns requires clinical context. Some negative reviews of Keeps specifically concern finasteride side effects, particularly sexual dysfunction. Separating company-level service failures from drug-level pharmacology matters when evaluating whether complaints represent negligence or expected pharmacology.

What Randomized Trials Show

The Proscar Long-Term Efficacy and Safety Study (PLESS, N=3,040) remains the largest randomized controlled trial of finasteride 5 mg for BPH, but its safety sub-analyses inform the 1 mg hair loss literature. A dedicated RCT of finasteride 1 mg (N=1,553, 2-year duration) published in the Journal of the American Academy of Dermatology found that 83% of men maintained hair count versus baseline and 66% showed visible improvement, compared with 7% improvement in placebo [5].

Sexual side effects, decreased libido, erectile dysfunction, ejaculatory disorders, occurred in approximately 1.4 to 2.1% of finasteride 1 mg patients versus 0.7 to 1.5% in placebo arms across registration trials. The absolute risk difference is small, though the subjective impact for affected individuals is not.

Post-Finasteride Syndrome: What the FDA Label Says

The FDA updated the finasteride label in 2012 to include post-marketing reports of persistent sexual dysfunction after discontinuation, now referred to by researchers as Post-Finasteride Syndrome [6]. The label language states: "sexual adverse experiences have been reported in patients taking finasteride 1 mg for male pattern hair loss. These adverse events, including libido decrease, erectile dysfunction, and ejaculation disorder, occurred in less than 2% of patients and resolved in men who discontinued therapy. Persistent sexual dysfunction after cessation of treatment has been reported rarely."

Keeps' clinical workflow requires patients to confirm they have read the drug's risk disclosures during intake. Complaints alleging that Keeps failed to disclose finasteride risks are inconsistent with this documented intake step, though individual prescriber thoroughness in the asynchronous model is harder to audit than in a traditional clinic visit.

Monitoring and Follow-Up

The American Academy of Dermatology's 2020 guidelines for androgenetic alopecia recommend patient follow-up at 3 to 6 months after initiating finasteride, with annual review thereafter [7]. Asynchronous telehealth platforms by definition provide less structured follow-up than in-person practices. Keeps offers check-in messaging, but the cadence depends on patient initiation. Men with comorbidities, particularly those of reproductive age considering fatherhood, or those with a family history of prostate cancer, should maintain in-person provider relationships alongside any telehealth hair loss subscription.

Minoxidil: Complaint Profile and Clinical Standing

Complaints about Keeps' minoxidil products are rarer and mostly involve product formulation or concentration preference rather than adverse events. Keeps offers both the standard 5% topical solution and, through some prescriber pathways, compounded minoxidil formulations.

OTC vs. Prescription Minoxidil Through Keeps

Minoxidil 5% topical solution is available OTC at any pharmacy. Keeps charges a subscription price that, for some consumers, exceeds the OTC retail cost for the same concentration. This pricing gap has generated a subset of complaints from users who feel they overpaid for a convenience markup. That is a consumer-choice issue, not a safety issue.

Oral minoxidil (0.625 mg to 2.5 mg) is increasingly used off-label for androgenetic alopecia. A systematic review published in JAMA Dermatology (2021) identified oral minoxidil as effective with an acceptable safety profile at low doses [8]. If Keeps' prescribers offer oral minoxidil, that prescription requires physician sign-off, it is not a self-service OTC product.

Reported Adverse Events and Proportion

Minoxidil's most common adverse effect is scalp irritation and contact dermatitis, affecting roughly 7% of users in clinical trial data, often attributable to the propylene glycol vehicle rather than minoxidil itself [9]. Systemic effects (fluid retention, tachycardia) are rare at topical doses but are a documented risk with oral minoxidil, particularly in patients with cardiac history.

No pattern of serious adverse events traced to Keeps-dispensed minoxidil appears in the FDA MedWatch FAERS database query as of mid-2025 [3].

How Keeps Compares to Competitors on the Complaint Dimension

Hims, Roman, and Numan operate nearly identical D2C hair loss subscription models. All four face similar BBB complaint profiles dominated by billing and cancellation friction. Hims' BBB file is substantially larger in absolute volume, consistent with Hims' larger subscriber base, but the complaint-type distribution is the same.

The FTC action against auto-renewal dark patterns in 2023 affected the entire D2C subscription health sector. Companies that did not proactively improve cancellation UX have continued to accumulate complaints.

Keeps is not uniquely problematic in its complaint profile. The better question for a prospective user is whether the subscription model matches their tolerance for auto-renewal management, not whether the drugs are safe or the prescribers are licensed.

What State Medical Boards and the FDA Show

A search of publicly available state medical board disciplinary actions does not surface any actions specifically naming Keeps Health, Inc. Or its medical director as of mid-2025. That is a meaningful data point. Board actions, license suspensions, consent orders, fines, represent the most serious signal of clinical misconduct.

The FDA's warning letter database [3] and the FTC's enforcement action database [4] similarly show no actions naming Keeps as of the date of this review. The absence of regulatory action does not guarantee perfect practice, but it is the standard against which telehealth platforms are properly evaluated.

What to Do If You Have a Complaint

If a consumer believes a billing dispute warrants escalation, the appropriate paths are:

• Filing a complaint with the BBB at bbb.org
• Filing an FTC complaint at reportfraud.ftc.gov
• If the dispute involves a prescriber's conduct, filing with the relevant state medical board
• If the dispute involves a pharmacy dispensing error, filing with the state board of pharmacy and the FDA MedWatch program

Clinical Decision Framework: Is Keeps Appropriate for You?

Not every patient is a good fit for an asynchronous telehealth hair loss platform, regardless of which brand they choose. The following framework, developed by the HealthRX clinical team for this review, identifies patients who are and are not well-served by this model.

Patients Who Fit the Asynchronous Model Well

Men with confirmed androgenetic alopecia (Norwood scale I to IV), no significant comorbidities, no reproductive plans in the near term, no personal or family history of prostate cancer, and who have already had a PSA baseline drawn are reasonable candidates for an asynchronous finasteride prescription through a platform like Keeps. The drug is well-studied, the risk profile is understood, and the monitoring requirements are modest.

Patients Who Need In-Person Evaluation First

Men with diffuse hair loss that does not follow an androgenetic pattern, men under age 18 (finasteride is contraindicated), men with a first-degree family history of prostate cancer who have not had recent PSA testing, men on 5-alpha reductase inhibitor therapies for other indications, and men with active cardiac history considering oral minoxidil should all establish care with an in-person dermatologist or urologist before or alongside any telehealth subscription.

The AAD 2020 guidelines state: "Patients with hair loss should undergo a thorough history and physical examination to identify potentially reversible causes before initiating treatment for androgenetic alopecia" [7]. An asynchronous photo-consult cannot fully substitute for this evaluation in ambiguous presentations.

Pricing, Subscription Mechanics, and the Complaint-Generation Loop

Keeps' pricing as of mid-2025 runs approximately $25 to $35 per month for finasteride 1 mg, with minoxidil adding another $10 to $20 monthly. The combined regimen costs roughly $35 to $55 per month, cheaper than brand-name Propecia ($70 to $100+ per month at retail) but more expensive than generic finasteride at a standard pharmacy ($10 to $20 per month with a GoodRx coupon).

The price premium funds the telehealth consultation, the prescription management, and the packaging. Whether that convenience is worth the premium depends on individual preference. What it also funds is the subscription infrastructure that generates the billing complaints on the BBB record.

Auto-ship subscriptions in health categories generate complaints at rates roughly three to five times higher than one-time purchases, according to FTC consumer protection research [4]. This structural fact explains more of Keeps' complaint volume than any specific company misconduct.